Selected article for: "active sars infection and acute respiratory"
Author: Nilius-Eliliwi, Verena; Mika, Thomas; Baraniskin, Alexander; Wünnenberg, Max; Maslova, Marina; Boy, Christian; Klein-Scory, Susanne; Schroers, Roland; Vangala, Deepak
Title: Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report
  • Cord-id: bk8sllle
  • Document date: 2021_7_14
    • ID: bk8sllle
    Snippet: In patients with compromised immune function, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (CoVID-19) impose particular challenges. Especially in hematological malignancies, including lymphoma, the demands by this novel virus disease are further enhanced during sophisticated treatments, such as chimeric antigen receptor (CAR) T-cell therapy. Here, we present the first case of a patient with refractory diffuse-large B-cell lymphoma, who under
    Document: In patients with compromised immune function, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (CoVID-19) impose particular challenges. Especially in hematological malignancies, including lymphoma, the demands by this novel virus disease are further enhanced during sophisticated treatments, such as chimeric antigen receptor (CAR) T-cell therapy. Here, we present the first case of a patient with refractory diffuse-large B-cell lymphoma, who underwent CAR T-cell treatment in the context of SARS-CoV-2. Irrespective of prolonged and active SARS-CoV-2 infection, T cells were successfully isolated by apheresis and processed to anti-CD19 CAR T cells (axicabtagene-ciloleucel). In light of the aggressive lymphoma course, lymphodepleting chemotherapy and CAR-T cells were administered in early recovery after oxygen-dependent CoVID-19 pneumonia. Except for moderate cytokine release, this cellular immunotherapy was well tolerated. Notably, there is no deterioration of the SARS-CoV-2 infection; however, complete lymphoma response and full clinical recovery were observed. In conclusion, CAR T-cell treatment in aggressive lymphoma in the setting of SARS-CoV-2 infection is feasible and may offer significant therapeutic activity in refractory disease.

    Search related documents:
    Co phrase search for related documents
    • active infection and long period: 1
    • active infection and long term outcome: 1
    • active infection and long term survival: 1, 2
    • active infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active infection and lymphodepleting chemotherapy: 1
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and long term survival: 1, 2
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome development and long period: 1
    • acute ards respiratory distress syndrome development and lung disease: 1, 2, 3, 4, 5, 6
    • admission pcr testing and lung ground glass opacity: 1
    • long period and lung disease: 1, 2
    • long term outcome and lung disease: 1, 2, 3
    • long term survival and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9